Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lacea Loader | Photo Supplied
Dr Molapo Qhobela, newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact.

The Council of the University of the Free State (UFS) approved the appointment of Dr Molapo Qhobela as Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact for a five-year term. Dr Qhobela will assume duty on 1 August 2021.

Extensive experience in the higher education sector

Dr Qhobela holds a PhD in Plant Pathology from the Kansas State University in the United States of America. His career started at Rhodes University in 1991, where he was a lecturer in microbiology and pharmacy, after which he joined the University of Cape Town before joining the public service sector. His leadership and strategic direction have been sought by several large and complex organisations in the course of his career. From 1998 to 2007, he was Chief Director: Higher Education Policy and Development Support in the Department of Education, from 2007 to 2009 he was Deputy Director General: Higher Education in the same department, and from 2010 to 2011 he was Deputy Director General: Human Capital and Knowledge Systems in the Department of Science and Technology. Dr Qhobela was appointed Vice-Principal: Institutional Development at the University of South Africa (UNISA) in 2011 and held the position until 2015. He was the Chief Executive Officer of the National Research Foundation (NRF) from 2016 to 2020. 

Strong governance credentials and a wealth of expertise

Dr Qhobela has strong governance credentials, having served and led governing boards, among others as the former chairperson of the boards of the Agricultural Research Council, the Global Research Council, and the Committee of Heads of Organisations of Research and Technology (COHORT). He is currently the chairperson of the Tertiary Education and Research Network of South Africa (TENET).

“Dr Qhobela brings a wealth of expertise, extensive networks, and partnerships – locally and internationally – to the UFS. His vast experience in previous roles places him in good standing to elevate institutional change, strategic partnerships, and societal impact at the university. His knowledge and understanding of the South African, African, and global higher education and research systems are extensive. I am confident that he will lead and manage the portfolio with clarity, dexterity, diplomacy, and integrity, and look forward to working with him to build and extend this important focus of the UFS,” says Prof Francis Petersen, UFS Rector and Vice-Chancellor. 

“I have devoted the majority of my professional career to the development of the country’s university and science system, during which time I have also worked with the previous and current leadership of the UFS. I can thus relate to the values and vision of the university as an engaged university that contributes to development and social justice through the production of globally competitive graduates and knowledge, and look forward to joining the institution,” says Dr Qhobela.  

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept